We have identified two patients with heterozygous de novo variants in RNF213 with severe, early‐onset moyamoya disease and stroke, but also with novel extra‐cerebral phenotypes, including chronic kidney disease, liver disease with elevated aminotransferases, and skin disease. This evidence concerns the gene RNF213 and Moyamoya disease.